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OBJECTIVES: To determine the demographic distribution and health care burden of 
patients diagnosed with rheumatoid arthritis (RA) using Medicare fee-for-service 
(FFS) data. METHODS: A retrospective analysis was performed using the 100% 
Medicare FFS datasets from October 1, 2008 through December 31, 2012. Patients 
diagnosed with RA were identified using International Classification of Diseases, 
9th Revision, Clinical Modification diagnosis code 714, and the first diagnosis date 
was designated as the index date. All patients were required to have continuous 
medical and pharmacy benefits 1 year pre- (baseline period) and post-index date 
(follow-up period). Health care resource utilization and costs during the baseline and 
follow-up periods were calculated. RESULTS: Using Medicare FFS data, 112,550 RA 
patients were identified. The average age at diagnosis was 76 years, and 72.54% of 
patients were women and 83.94% were white. The most common baseline comor-
bidities were diabetes (35.48%), followed by chronic obstructive pulmonary disease 
(30.83%) and cerebrovascular disease (21.50%). During the follow-up period, 66.35% 
of patients had inpatient admissions, 49.01% had emergency room visits, 87.93% 
had outpatient office visits, 87.93% had outpatient visits and 61.67% had pharmacy 
visits and costs were, on average, $26,510, $256, $4,204, $4,460 and $6,249, respec-
tively. The average total costs incurred by RA patients were $37,219. The five most 
commonly-prescribed medications prescribed to treat RA were prednisone (3.40%), 
levothyroxine sodium (2.63%), hydrocodone bit/acetaminophen (2.39%), furosemide 
(2.13%) and omeprazole (2.13%). CONCLUSIONS: RA patient demographic distri-
butions and RA-related health care cost information was obtained and the most 
commonly prescribed medications to treat RA were identified.
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OBJECTIVES: This study evaluated the comparative risk of transfusion, in-
hospital complications, and incremental total hospitalization costs of primary 
unilateral, simultaneous bilateral, and revision total knee arthroplasty (TKA) proce-
dures. METHODS: Using the Premier Database from 1/1/2008 – 6/30/2014, we identi-
fied adults 18+ years old who underwent primary unilateral, simultaneous bilateral, 
or revision TKA procedure. Patients with multiple orthopedic procedures during the 
hospitalization, fracture diagnoses, and oncologic diagnosis were excluded. Logistic 
regressions – controlling for age, sex, region, hospital size, academic status, payor, 
procedure year, obesity diagnosis, and Charlson Score – were used to determine the 
risk of autologous or allogeneic blood transfusion. Generalized linear models (GLM) 
– controlling for the same factors – predicted the incremental total hospitalization 
cost associated with transfusion. RESULTS: 513,558 primary (mean age, 66; 37% 
male), 33,977 bilateral (mean age, 63, 43% male), and 32,494 revision (mean age 65, 
41% male) TKA patients met selection criteria. The overall percentage transfused 
was 14.1%, 36.3%, and 20.0%, respectively. Regressions indicated the following fac-
tors were significantly associated with higher transfusion risk: age > 65, females, 
residing in the Northeast, large hospitals, and higher Charlson Score. Though risk 
of transfusion decreased over the study period, the highest comorbidity (Charlson 
3+) patients were at 2.27 (primary), 1.88 (bilateral), and 2.44 (revision) greater odds 
of transfusion vs healthy controls. Unadjusted total hospitalization costs were 
$17,685, $28,557, and $26,972 for each procedure, respectively. GLM results showed 
an incremental total hospitalization cost among those with transfusion vs. without 
of $2,840, $4,985, and $9,267, respectively. CONCLUSIONS: Transfusion risk, while 
decreasing over recent years, is still a burden in select patient populations and 
procedures. The incremental cost of requiring a transfusion is significant, including 
not only direct costs of blood administration but staff time and increased hospital 
resource use. Strategies to decrease transfusion risk among select patient popula-
tions are warranted.
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OBJECTIVES: This study evaluated the correlation between patient comorbid-
ity status and total hospitalization length of stay (LOS) and cost for total knee 
arthroplasty (TKA), total hip arthroplasty (THA), and one to three level lumbar 
spinal fusion procedures. METHODS: Using the Premier Database from 1/1/2008 
– 6/30/2014, we identified adults 18+ years old with a primary procedure of TKA, 
THA, or spinal fusion. Patients with multiple orthopedic procedures during the 
hospitalization, fracture diagnoses, and revision procedures were excluded. 
Mean hospital length of stay (LOS) was compared by Charlson Score with ANOVA. 
Generalized linear models (GLM) – controlling for age, sex, region, hospital size, 
academic status, payor, and procedure year – predicted the incremental total hos-
pitalization cost among the sickest patients (Charlson ≥ 3) vs healthy controls 
(Charlson zero). RESULTS: 536,582 TKA (mean age, 66; 37% male), 275,953 THA 
(mean age, 64, 45% male), and 177,493 fusion (mean age 57, 44% male) patients met 
selection criteria. Mean ± SD Charlson Scores were 0.67 ± 0.97, 0.57 ± 0.95, and 0.57 
± 0.92, and the percent with a Charlson of ≥ 3 were 5.4%, 4.7%, and 4.3%. Mean LOS 
increased by 0.9 ± 1.5, 1.4 ± 2.3, and 2.3 ± 3.8 days for patients with a Charlson of ≥ 
3 vs zero for each procedure, respectively. Unadjusted total hospitalization costs 
were $17,512, $18,915, and $32,932, respectively. GLM results showed an incre-
mental total hospitalization cost of a Charlson Score of ≥ 3 vs. 0 of $2,211, $3,041, 
and $3,922 for each procedure, respectively. CONCLUSIONS: While a relatively 
small proportion of all patients undergoing elective orthopedic procedures, the 
sickest patients (Charlson ≥ 3) were associated with a significant hospitalization 
cost burden. With patient comorbidity burden growing nationally, this study war-
rants further examination of improved standards of care for comorbid patients 
undergoing elective orthopedic procedures.
day); abatacept (750 mg weeks 0-2-4 and then every 4 weeks); adalimumab (40mg 
every two weeks); certolizumab (400mg at weeks 0-2, 4 and then 200mg every 4 
weeks); etanercept (50mg/week); golimumab (50mg/month); infliximab (3mg/kg 
weeks 0-2-6 and then every 8 weeks); rituximab (1000mg weeks 0-2 and then 24 
weeks after); tocilizumab 8mg/kg every 4 weeks). Dosage information was taken 
from Instituto de Salud Publica de Chile, an average weight of 70kg was consid-
ered for those drugs whose dose depends of weight. Results are expressed in 
2014USD (exchange rate US$1 = CLP$600) RESULTS: In a time horizon of one year, 
the costs associated with the RA treatment were in average: US$93.83 diagnosis, 
US$269.19 monitoring, US$59.73 concomitant drugs. The annual cost of RA treat-
ment with available drugs after conventional csDMARDs failure was estimated 
between US$9,378.4 (tofacitinib) and US$18,368.9 (abatacept) as highest and low-
est options. CONCLUSIONS: For the analyzed scenario, tofacitinib is the option 
with lower costs, generating savings in comparison with the biological therapies 
available for RA after csDMARDs failure.
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OBJECTIVES: Bone loss and fractures following initiation of androgen deprivation 
therapy (ADT) result in excess healthcare costs. There is limited information regard-
ing the extent to which these costs depend on the patient’s comorbidity profile. We 
examined the influence of baseline comorbidity status on the incremental cost of 
fractures in older men with non-metastatic PCa and treated with ADT. METHODS: 
Using linked Surveillance, Epidemiology, and End Results & Medicare data, we iden-
tified men aged 66+ with incident non-metastatic PCa diagnosed during 2000-2005 
and treated with ADT. Patients were followed until death or up to 5 years after ADT 
initiation. Total direct medical costs, in 2010 dollars, were calculated for each month. 
To account for censoring, monthly costs were weighted by the inverse probability 
of being uncensored. Partitioned weighted least squares regression models were 
estimated to determine the incremental cost of fractures for subgroups defined 
by the baseline Charlson Comorbidity Index (CCI). RESULTS: Application of study 
inclusion criteria resulted in 30,904 men with non-metastatic PCa (median age: 76 
years), of whom 57% had 5 years of follow-up, 28% died, and 15% were censored. 
The mean (interquartile range) unadjusted 5-year total cost was $77,244 ($35,366 
- $97,087), and was higher (p< 0.01) for men with baseline congestive heart failure, 
chronic renal failure, and diabetes with complications. During follow-up, 6,779 men 
(22%) experienced a fracture, and the mean (median) time from ADT initiation to 
first fracture was 25.1 (22.8) months. The adjusted incremental cost of fractures was 
$33,650 on average and varied by baseline CCI as follows: $31,800 among patients 
with CCI= 0; $34,320 among patients with CCI= 1; and $46,678 among patients with 
CCI= 2 or higher. CONCLUSIONS: Among older men with PCa treated with ADT, the 
incremental cost of fractures was highest among those with greater comorbidity 
burden.
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OBJECTIVES: To investigate the health care cost burden and demographic distribution 
of patients diagnosed with psoriatic arthritis (PSA) in the Medicare fee-for-service 
(FFS) Dataset. METHODS: A retrospective database analysis was performed using 
the 100% Medicare FFS Datasets from October 1, 2008 through December 31, 2012. 
Patients diagnosed with PSA were identified using International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 696.0, and 
the index date was the date of the initial diagnosis. All patients were required to have 
continuous medical and pharmacy benefits 1-year pre- and post-index date. Health 
care costs and utilization during the baseline (1 year before the diagnosis date) and 
follow-up (1 year after the diagnosis date) periods were calculated. RESULTS: Using 
the aforementioned criteria, 11,324 PSA patients were identified. The average age 
at diagnosis was 74 years, 66.10% of patients were women and almost 92.36% were 
white. The majority of patients resided in the South U.S. region (39.01%). Diabetes 
(33.84%), chronic obstructive pulmonary disease (29.04%) and cerebrovascular disease 
(17.36%) were the main comorbidities observed during the baseline period. During 
the follow-up period, 62.96% of patients had inpatient admissions, 47.29% had emer-
gency room visits, 91.67% had outpatient office visits, 91.67% had outpatient visits 
and 58.03% had pharmacy visits, costing, on average, $23,960, $237, $5,015, $5,252 
and $7,335, respectively. The average total cost of PSA patients was $36,548. The five 
most commonly prescribed medications for PSA were methotrexate sodium (4.54%), 
prednisone (3.37%), levothyroxine sodium (2.59%), hydrocodone bit/acetaminophen 
(2.43%) and simvastatin (2.11%). CONCLUSIONS: PSA patient demographic and health 
care cost information was obtained and the most commonly prescribed PSA medica-
tions were identified.
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